CASI Pharmaceuticals (CASI) 10-K 21 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 14, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'ENMD	'	'
Entity Common Stock, Shares Outstanding	'	27,040,429	'
Entity Registrant Name	'ENTREMED INC	'	'
Entity Central Index Key	'0000895051	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$51,879,703

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$15,131,671	$8,049,237
Accounts receivable, net of allowance for doubtful accounts of $12,536 at December 31, 2013 and 2012	0	669,310
Prepaid expenses and other	279,773	189,465
Total current assets	15,411,444	8,908,012
Property and equipment, net	78,142	52,556
Other assets	17,965	17,427
Total assets	15,507,551	8,977,995
Current liabilities:	'	'
Accounts payable	402,456	504,851
Payable to related party	0	86,683
Accrued liabilities	162,710	151,219
Total current liabilities	565,166	742,753
Commitments and Contingencies	0	0
Stockholders' equity:	'	'
Convertible preferred stock, $1.00 par value; 5,000,000 shares authorized and 0 shares issued and outstanding at December 31, 2013 and 2012	0	0
Common stock, $.01 par value: 170,000,000 shares authorized at December 31, 2013 and 2012; 27,119,974 and 22,582,938 shares issued and outstanding at December 31, 2013 and 2012, respectively	271,198	225,828
Additional paid-in capital	421,775,039	409,374,905
Treasury stock, at cost: 79,545 shares held at December 31, 2013 and 2012	-8,034,244	-8,034,244
Accumulated deficit	-399,069,608	-393,331,247
Total stockholders' equity	14,942,385	8,235,242
Total liabilities and stockholders' equity	$15,507,551	$8,977,995

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets [Parenthetical] (USD $)	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts (in dollars)	$12,536	$12,536
Convertible preferred stock, par value (in dollars per share)	$1	$1
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	170,000,000	170,000,000
Common stock, shares issued	27,119,974	22,582,938
Common Stock, Shares, Outstanding	27,119,974	22,582,938
Treasury stock, shares held	79,545	79,545

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Royalties	$0	$669,310
Revenues	0	669,310
Costs and expenses:	'	'
Research and development	2,749,430	2,375,339
General and administrative	2,990,589	2,797,971
Costs and expenses	5,740,019	5,173,310
Interest (income) expense, net	-1,658	10,041,224
Net loss	-5,738,361	-14,545,224
Dividends on Series A convertible preferred stock	0	-335,000
Net loss attributable to common shareholders	($5,738,361)	($14,880,224)
Net loss per share (basic and diluted) (in dollars Per share)	($0.22)	($0.78)
Weighted average number of common shares outstanding (basic and diluted) (in shares)	26,125,852	19,055,064

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2011	$2,531,743	$3,350,000	$122,376	($8,034,244)	$385,879,634	($378,786,023)
Balance (in shares) at Dec. 31, 2011	'	3,350,000	12,158,099	'	'	'
Issuance of common stock for options exercised	1,999	0	11	0	1,988	0
Issuance of common stock for options exercised (in shares)	'	0	1,136	'	'	'
Conversion of preferred stock into common stock	0	-3,350,000	15,227	0	3,334,773	0
Conversion of preferred stock into common stock (in shares)	'	-3,350,000	1,522,727	'	'	'
Issuance of common stock pursuant to financing agreements	10,055,801	0	88,214	0	9,967,587	0
Issuance of common stock pursuant to financing agreements (in shares)	'	0	8,821,431	'	'	'
Stock-based compensation expense, net of forfeitures	978,243	0	0	0	978,243	0
Fair value of warrants issued pursuant to the 2012 Financing (Note 6)	2,155,527	0	0	0	2,155,527	0
Fair value of beneficial conversion of notes pursuant to the 2012 Financing (Note 6)	7,057,153	0	0	0	7,057,153	0
Net loss	-14,545,224	0	0	0	0	-14,545,224
Balance at Dec. 31, 2012	8,235,242	0	225,828	-8,034,244	409,374,905	-393,331,247
Balance (in shares) at Dec. 31, 2012	'	0	22,503,393	'	'	'
Issuance of common stock for options exercised	7,190	0	38	0	7,152	0
Issuance of common stock for options exercised (in shares)	'	0	3,817	'	'	'
Issuance of common stock for warrants exercised	52,347	0	374	0	51,973	0
Issuance of common stock for warrants exercised (in shares)	'	'	37,391	'	'	'
Issuance of common stock pursuant to financing agreements	6,652,255	0	44,958	0	6,607,297	0
Issuance of common stock pursuant to financing agreements (in shares)	'	0	4,495,828	'	'	'
Stock-based compensation expense, net of forfeitures	2,044,382	0	0	0	2,044,382	0
Fair value of warrants issued pursuant to the 2012 Financing (Note 6)	3,689,330	0	0	0	3,689,330	0
Net loss	-5,738,361	0	0	0	0	-5,738,361
Balance at Dec. 31, 2013	$14,942,385	$0	$271,198	($8,034,244)	$421,775,039	($399,069,608)
Balance (in shares) at Dec. 31, 2013	'	0	27,040,429	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($5,738,361)	($14,545,224)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	17,389	20,457
Stock-based compensation expense	2,044,382	978,243
Non-cash interest	0	10,041,292
Changes in operating assets and liabilities:	'	'
Accounts receivable	669,310	1,263,432
Prepaid expenses and other	-90,846	-9,051
Accounts payable	-102,395	51,522
Payable to related party	-86,683	86,683
Accrued liabilities	11,491	-99,543
Net cash used in operating activities	-3,275,713	-2,212,189
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchases of furniture and equipment	-42,975	-48,392
Net cash used in investing activities	-42,975	-48,392
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from issuance of convertible notes and warrants	0	10,000,000
Debt issuance costs	0	-683,955
Proceeds from sale of common stock and warrants	10,789,987	0
Stock issuance costs	-448,402	-88,856
Proceeds from exercise of options and warrants	59,537	1,999
Net cash provided by financing activities	10,401,122	9,229,188
Net increase in cash and cash equivalents	7,082,434	6,968,607
Cash and cash equivalents at beginning of year	8,049,237	1,080,630
Cash and cash equivalents at end of year	15,131,671	8,049,237
Non-cash financing activity:	'	'
Common stock issued in connection with conversion of convertible notes and accrued interest	0	10,144,658
Common stock issued in connection with conversion of preferred stock	0	3,500,000
Warrant issued to placement agent	115,150	0
Non-cash investing activity:	'	'
Disposal of fully depreciated property and equipment, at cost	$123,980	$129,672

DESCRIPTION_OF_BUSINESS_AND_BA

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Accounting [Text Block]	'
	1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
	EntreMed, Inc. and its subsidiaries (“EntreMed” or “the Company”) (Nasdaq: ENMD) is a clinical-stage pharmaceutical company employing a drug development strategy that leverages resources in both North America and in China to develop therapeutics for the treatment of cancer and other diseases. The Company is currently conducting activities in both China and North America in order to accelerate delivery of clinical data and to reduce costs of clinical trials. The Company’s lead drug candidate is ENMD-2076, a selective Aurora A and angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed Phase 1 studies in patients with advanced solid tumors, multiple myeloma and leukemia and is currently completing data for a multi-center Phase 2 study in patients with platinum resistant ovarian cancer. In 2012, the Company initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Additionally, in January 2013, the Company initiated a Phase 2 trial in advanced/metastatic soft tissue sarcoma, and in October 2013, the Company initiated a Phase 2 trial in advanced ovarian clear cell carcinoma. The Company intends to pursue additional trials and is in various assessment and planning stages. The Company employs a market-oriented approach to identify pharmaceutical candidates that it believes has the potential for gaining widespread market acceptance either globally or in China and for which development can be accelerated under the Company’s US and China drug development strategy.
	ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 exerts its effects through multiple mechanisms of action, including anti-proliferative activity and the inhibition of angiogenesis. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3, and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has demonstrated significant, dose-dependent preclinical activity as a single agent, including tumor regression, in multiple xenograft models (e.g. breast, colon, leukemia), as well as activity towards ex vivo-treated human leukemia patient cells. ENMD-2076 also has shown promising activity in Phase 1 clinical trials in solid tumor cancers, including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma. The Company is completing a Phase 2 trial of ENMD-2076 in ovarian cancer. In addition, EntreMed is currently conducting a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and a Phase 2 study in advanced ovarian clear cell carcinoma.
	ENMD-2076 has received orphan drug designation for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.
	ENMD-2076 is the only program currently under active clinical evaluation. Other product candidates in the pipeline include 2-methoxyestrdiol (2ME2) for autoimmune diseases for which the Company has an approved Investigational New Drug Application in rheumatoid arthritis treatment and MKC-1. The Company owns or has exclusive license to these products.
	The Company intends to advance clinical development of ENMD-2076 and the implementation of its plans will include leveraging resources in both the United States and China. In order to capitalize on the drug development and capital resources available in China, the Company is doing business in China through its wholly-owned Chinese subsidiary. The Chinese subsidiary will execute the China portion of the Company’s drug development strategy, including conducting clinical trials in China, pursuing local funding opportunities and strategic collaborations, and implementing the Company’s plan for accelerated development and commercialization in the Chinese market.
	The Company intends to pursue additional financing opportunities as well as opportunities to raise capital through forms of non- or less- dilutive arrangements, such as partnerships and collaborations with organizations that have capabilities and/or products that are complementary to our capabilities and products in order to continue the development of the product candidate that the Company intends to pursue to commercialization.
	The accompanying consolidated financial statements include the accounts of EntreMed, Inc. and its subsidiaries, Miikana Therapeutics, Inc. (Miikana) and EntreMed (Beijing) Co., Ltd. (EntreMed China). EntreMed China is a non-stock Chinese entity with 100% of its interest owned by EntreMed. EntreMed China received approval for a business license from the Beijing Industry and Commercial Administration in August 2012 and has operating facilities in Beijing. All inter-company balances and transactions have been eliminated in consolidation.
	LIQUIDITY RISKS AND MANAGEMENT’S PLANS
	Since inception, the Company has incurred significant losses from operations and has incurred an accumulated deficit of $399.1 million.  The Company expects to continue to incur operating losses for the foreseeable future due to, among other factors, its continuing clinical activities. In February 2012 (the “2012 Financing”), the Company received the proceeds from a $10 million convertible note financing. Upon approval by the Company’s stockholders at the 2012 annual stockholders meeting, the convertible notes automatically converted into common stock on May 1, 2012 (see Note 6). In addition, on March 14, 2013 (the “2013 Financing”), the Company closed on the sale of 4,495,828 shares of common stock and 2,247,912 warrants to certain investors for approximately $10.8 million (see Note 6). As a result of these transactions, along with on-going cost containment measures, the Company has sufficient resources to fund its operations for at least the next twelve months. The Company will continue to exercise tight controls over operating expenditures and will continue to pursue opportunities, as required, to raise additional capital and will also actively pursue non- or less-dilutive arrangements in China to support the Company’s dual-country approach to drug development.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies [Text Block]	'
	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	SEGMENT INFORMATION
	The Company currently operates in one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer. The Company is managed and operated as one business. EntreMed’s senior management team reports to the Board of Directors and is responsible for aligning the Company’s business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability. The Company employs a drug development strategy in the United States and China to develop targeted therapeutics for the global market and its current lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer.
	The Company does not operate separate lines of business with respect to its product candidates. Accordingly, the Company does not have separately reportable segments as defined by authoritative guidance issued by the Financial Accounting Standards Board (FASB).
	RESEARCH AND DEVELOPMENT
	Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical correlative testing and clinical trials of our drug candidate, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development costs are expensed as incurred, including costs incurred in filing, defending and maintaining patents.
	PROPERTY AND EQUIPMENT
	Furniture and equipment and leasehold improvements are stated at cost and are depreciated over their estimated useful lives of 3 to 10 years. Depreciation and amortization is determined on a straight-line basis. Depreciation and amortization expense was $17,389 and $20,457 in 2013 and 2012, respectively.
	Property and equipment consists of the following:
		DECEMBER 31,
		2013		2012
	Furniture and equipment	$	248,732	$	235,093
	Leasehold improvements		6,382		101,026
			255,114		336,119
	Less: accumulated depreciation and amortization		-176,972		-283,563
		$	78,142	$	52,556
	IMPAIRMENT OF LONG-LIVED ASSETS
	In accordance with authoritative guidance issued by FASB, the Company periodically evaluates the value reflected in its balance sheet of long-lived assets, such as equipment, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Such events and circumstances include the use of the asset in current research and development projects, any potential alternative uses of the asset in other research and development projects in the short to medium term and restructuring plans entered into by the Company. No impairment charges were recorded in 2013 and 2012.
	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents include cash and highly liquid investments with original maturities of less than 90 days. Substantially all of the Company's cash equivalents are held in short-term money market accounts.
	ACCOUNTS RECEIVABLE
	Accounts receivable are stated net of allowances for doubtful accounts.  Allowances for doubtful accounts are determined on a specific item basis.  Management reviews the credit worthiness of individual customers and past payment history to determine the allowance for doubtful accounts.  There is an allowance for doubtful accounts of $12,536 at December 31, 2013 and 2012.
	As of December 31, 2012, one customer represented 100% of the total accounts receivable.
	FOREIGN CURRENCY TRANSLATION
	The U.S. dollar is the functional and reporting currency of the Company. Foreign currency denominated assets and liabilities of the Company and all of its subsidiaries are translated into U.S. dollars. Accordingly, monetary assets and liabilities are translated using the exchange rates in effect at the consolidated balance sheet date and revenues and expenses at the rates of exchange prevailing when the transactions occurred. Remeasurement adjustments are included in income.
	DEFERRED RENT
	The Company accounts for rent expense related to operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense in each fiscal year is recorded as an adjustment to deferred rent. Deferred rent as of December 31, 2013 and 2012 was $6,871 and $2,029, respectively, and is included in accrued liabilities in the accompanying consolidated balance sheets.
	DEBT ISSUANCE COST
	Amortization expense of debt issuance costs is calculated using the interest method over the term of the debt and is recorded in interest expense for 2012 in the accompanying consolidated statements of operations.
	CONVERTIBLE NOTES WITH DETACHABLE WARRANTS AND BENEFICIAL CONVERSION FEATURE
	The Company accounts for the issuance of detachable stock purchase warrants in accordance with Accounting Standards Codification (ASC) Topic 470, whereby the proceeds received from convertible notes are allocated between the convertible notes and the detachable warrants based on the relative fair value of the convertible notes without the warrants and the warrants. The portion of the proceeds allocated to the warrants is recognized as additional paid-in capital and a debt discount. The debt discount related to warrants is accreted into interest expense through maturity of the notes.
	In accordance with the provisions of ASC Topic 470, the Company allocated a portion of the proceeds received in connection with the 2012 Financing to the embedded beneficial conversion feature, based on the difference between the effective conversion price of the proceeds allocated to the convertible notes and the fair value of the underlying common stock on the date the convertible notes were issued. Since the convertible notes also had detachable stock purchase warrants, the Company first allocated the proceeds to the stock purchase warrants and the convertible notes and then allocated the resulting convertible notes proceeds between the beneficial conversion feature, which was accounted for as paid-in capital, and the initial carrying amount of the convertible notes. The discount resulting from the beneficial conversion feature is recorded as a debt discount.
	EXPENSES FOR CLINICAL TRIALS
	Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. The Company estimates expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and the length of participation for each patient. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, the Company accrues an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial. As of December 31, 2013 and 2012, clinical trial accruals were $244,192 and $222,304, respectively, and are included in accounts payable in the accompanying consolidated balance sheets.
	INCOME TAXES
	Income tax expense is accounted for in accordance with authoritative guidance issued by FASB. Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.
	The Company accounts for uncertain tax positions pursuant to the guidance of FASB ASC Topic 740, Income Taxes. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. As of December 31, 2013 and 2012, the Company did not accrue any interest related to uncertain tax positions. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes.
	REVENUE RECOGNITION
	Revenue is not recognized until it is realized or realizable and earned. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed and determinable and collectibility is reasonably assured. Royalties from licenses are based on third-party sales and recorded as earned in accordance with contract terms, when third-party results are reliably measured and collectibility is reasonably assured.
	All of the Company’s 2012 revenues were from royalties based on the sale of Thalomid®, distributed by Celgene Corporation (“Celgene”). In 2004, certain provisions of a purchase agreement dated June 14, 2001 by and between Bioventure Investments kft (“Bioventure”) and the Company were satisfied, and, as a result, in 2005 the Company became entitled to share in the royalty payments received by Royalty Pharma Finance Trust, successor to Bioventure, on annual Thalomid® sales above a certain threshold. Based on the licensing agreement royalty formula, the Company’s right to share in the annual royalty commences when net royalties received by Royalty Pharma exceeds $15,375,000. The Company did not recognize any royalty revenue in 2013, as it did not meet the threshold to earn royalties on the sale of Thalomid® in 2013. The Company does not expect to earn royalties from the sale of Thalomid® in any subsequent year.
	NET LOSS PER SHARE
	Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Outstanding options and warrants totaling 7,907,959 and 3,686,338 for 2013 and 2012, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.
	SHARE-BASED COMPENSATION
	The Company records compensation expense associated with service, performance, market condition based stock options and other equity-based compensation in accordance with provisions of authoritative guidance. The fair value of awards whose fair values are calculated using the Black-Scholes option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The fair value of awards with market conditions, which are valued using a binomial model, is being amortized based upon the derived service period. Share based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. As of December 31, 2013, no expense has been recorded for share awards with performance conditions.
	NEW ACCOUNTING PRONOUNCEMENTS
	EntreMed has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements.
	FAIR VALUE OF FINANCIAL INSTRUMENTS AND CONCENTRATIONS OF RISK
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured amounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. The carrying amount of current assets and liabilities approximates their fair values due to their short-term maturities.
	USE OF ESTIMATES
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our most critical accounting estimates relate to accounting policies for clinical trial accruals and share-based arrangements. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	3. RELATED PARTY TRANSACTIONS
	On October 31, 2012, EntreMed China obtained the necessary local regulatory approvals to establish a bank account in Beijing. Prior to establishing a bank account, EntreMed China incurred certain startup and initial operating expenses, which were advanced by the Company’s Chief Executive Officer on behalf of EntreMed China, totaling $86,683. The full amount was repaid to the Company’s Chief Executive Officer in February 2013.
	In connection with the successful completion of the 2012 Financing, as discussed in Note 6 below, and prior to his appointment to the Board of Directors, the Company paid a 6% advisory fee to Emerging Technology Partners LLC, of which the Company’s Chairman is a general partner, for due diligence, its role in structuring and negotiating the transaction and as reimbursement for fees incurred. The 2012 Financing was approved by stockholders at the Company’s annual meeting in 2012.

LICENSE_AGREEMENTS

LICENSE AGREEMENTS	12 Months Ended
	Dec. 31, 2013
License Agreements [Abstract]	'
License Agreements [Text Block]	'
	4. LICENSE AGREEMENTS
	Pursuant to a purchase agreement dated June 14, 2001 by and between and the Company, as amended July 13, 2001, July 30, 2001 and August 3, 2001, Bioventure purchased all of the Company’s right, title and interest to the net royalty payments payable by Celgene to the Company under the agreement dated as of December 9, 1998 by and between the Company and Celgene (the “Celgene Sublicense”).
	A provision of the Bioventure purchase agreement provided the potential for an adjustment in the purchase price if cumulative sales of Thalomid® exceeded $800 million by December 31, 2004. Based on Thalomid® sales reported publicly by Celgene, the Company concluded that cumulative Thalomid® sales had reached this milestone by December 31, 2004, thus triggering a royalty sharing provision. Beginning the year after cumulative sales reach $800 million, EntreMed is entitled to share in the royalty payments received by Royalty Pharma Finance Trust, successor to Bioventure, on annual Thalomid® sales above a certain threshold. The Company is entitled to receive these sub-royalty payments until the last relevant patent expires, as described under the agreement. In 2012 Thalomid® sales surpassed the royalty-sharing point and the Company recognized royalty revenues of $669,310. The Company did not earn any royalties under the royalty sharing provision in 2013 and does not expect to earn any in the future.
	In January 2006, the Company entered into a License Agreement with Elan Corporation, plc (“Elan”) in which the Company has been granted rights to utilize Elan’s proprietary NanoCrystal Technology in connection with the development of the oncology product candidate, 2ME2 NCD. Under the terms of the License Agreement, Elan is eligible to receive payments upon the achievement of certain clinical, manufacturing, and regulatory milestones and to receive royalty payments based on sales of 2ME2 NCD. Additionally, under the agreement and the corresponding Services Agreement, Elan has the right to manufacture EntreMed’s 2ME2 NCD. Milestones related to the initiation of Phase 2 clinical trials for 2ME2 NCD have been paid and there are no additional milestones achieved as of December 31, 2013. The Company does not expect to achieve any milestones in 2014, as the Company does not expect to devote any significant resources to develop 2ME2 utilizing the NCD formulation.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	5. INCOME TAXES
	The income tax provision is based on loss before income taxes of $(5,314,629) in the U.S. and $(423,732) in China. The Company has net operating loss carryforwards for income tax purposes of approximately $343,555,000 at December 31, 2013 ($339,553,000 at December 31, 2012) that expire in years 2018 through 2033. The Company also has research and development (R&D) tax credit carryforwards of approximately $9,037,000 as of December 31, 2013 that expire in years 2018 through 2033. These net operating loss carryforwards include approximately $20,000,000, related to exercises of stock options for which the income tax benefit, if realized, would increase additional paid-in capital. The utilization of the net operating loss and research and development carryforwards may be limited in future years due to changes in ownership of the Company pursuant to Internal Revenue Code Section 382. For financial reporting purposes, a valuation allowance has been recognized to reduce the net deferred tax assets to zero due to uncertainties with respect to the Company's ability to generate taxable income in the future sufficient to realize the benefit of deferred income tax assets.
	Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred income tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		DECEMBER 31,
		2013		2012
	Deferred income tax assets (liabilities):
	Net operating loss carryforwards	$	134,395,000	$	132,994,000
	Research and development credit carryforward		9,037,000		9,019,000
	Equity investment		72,000		72,000
	Other		4,361,000		3,665,000
	Depreciation		4,000		64,000
	Valuation allowance for deferred income tax assets		-147,869,000		-145,814,000
	Net deferred income tax assets	$	-	$	-
	A reconciliation of the provision for income taxes to the federal statutory rate is as follows:
		2013		2012
	Tax benefit at statutory rate	$	-1,951,000	$	-4,945,000
	State taxes		-217,000		-701,000
	Net R&D credit adjustment		-122,000		-97,000
	Attribute expiration and other		8,000		4,068,000
	Disallowed expenses		2,000		1,000
	Change in valuation allowance		2,055,000		2,015,000
	Other		231,000		67,000
	Change in tax rates		-6,000		-408,000
		$	-	$	-
	The Company had $3,006,000 of unrecognized tax benefits as of January 1, 2013 related to net R&D tax credit carryforwards. The Company had a full valuation allowance on the net deferred tax asset recognized in the consolidated financial statements. For the year ended December 31, 2013, there were additional unrecognized tax benefits of $33,000 related to R&D tax credits, and a reduction in unrecognized tax benefits of $26,000 related to the remeasurement of certain prior year R&D credit carryforwards. The Company has a full valuation allowance at January 1, 2013 and at December 31, 2013 against the full amount of its net deferred tax assets and therefore, there was no impact on the Company’s financial position.
	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
		2013		2012
	Unrecognized tax benefits balance at January 1	$	3,006,000	$	3,103,000
	Reductions for Tax Positions of Prior Periods		-26,000		-97,000
	Additions for Tax Positions of Current Period		33,000		-
	Unrecognized tax benefits balance at December 31	$	3,013,000	$	3,006,000
	The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. As of December 31, 2013 and 2012, the Company had no accrued interest or penalties related to uncertain tax positions, respectively.
	The tax returns for all years in the Company’s major tax jurisdictions are not settled as of December 31, 2013. Due to the existence of tax attribute carryforwards (which are currently offset by a full valuation allowance), the Company treats all years’ tax positions as unsettled due to the taxing authorities’ ability to modify these attributes.
	The Company believes that the total unrecognized tax benefit, if recognized, would impact the effective rate, however, such reversal may be offset by a corresponding adjustment to the valuation allowance.

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2013
Stockholders Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	6. STOCKHOLDERS' EQUITY
	In 2002, the Company issued 3,350,000 shares of Series A Convertible Preferred Stock (“Series A Preferred Stock”) to Celgene. The value of the common stock at the date the Series A Preferred Stock was issued was $9.46. The Series A Preferred Stock was convertible, at the option of Celgene, at any time, into common stock at an initial per common share conversion price of $11.00 (1 share of preferred converts into .45 shares of common). The conversion price was subject to change for certain dilutive events, as defined. The Series A Preferred Stock accrued and accumulated dividends at a rate of 6% and participated in dividends declared and paid on the common stock, if any. In connection with the 2012 Financing, as described below, and upon stockholder approval of the 2012 Financing at the 2012 annual meeting on April 30, 2012, Celgene converted all of its preferred stock to an aggregate of 1,522,727 shares of common stock, pursuant to the terms and conditions of the Series A Preferred Stock. As a result, as of May 1, 2012, there is no Series A Preferred Stock or any class of preferred stock outstanding. As of April 30, 2012, cumulative unpaid preferred stock dividends totaled $9,380,000, or $2.80 per share. In connection with the stockholder approval of the 2012 Financing, Celgene waived all accrued dividends on the Series A Preferred Stock, and Celgene is no longer entitled to any liquidation preference on its shares.
	2013 FINANCING
	As described in Note 1 and in connection with the 2013 Financing, on March 1, 2013, the Company entered into a definitive agreement with certain investors (collectively, the “2013 Investors”) for a financing in the aggregate amount of approximately $10.8 million.  In connection with the 2013 Financing, the Company entered into a Securities Purchase Agreement with the 2013 Investors pursuant to which the Company agreed to sell in a transaction registered under the Securities Act of 1933, as amended, 4,495,828 shares of the Company’s common stock and warrants to purchase up to an aggregate of 2,247,912 shares of common stock (the “2013 Warrants”).  The 2013 Warrants cover a number of shares of common stock equal to 50% of the number of shares purchased by each 2013 Investor.  The 2013 Warrants have an exercise price of $2.91 per share and became exercisable on September 4, 2013 and expire on September 4, 2016. The fair value of the 2013 Warrants issued is $3,574,180, calculated using the Black-Scholes-Merton valuation model value of $1.59 with an expected and contractual life of 3.5 years, an assumed volatility of 102.3%, and a risk-free interest rate of 0.40%. The Company completed the closings on the 2013 Financing on March 14, 2013 and received net proceeds of approximately $10.3 million.
	In connection with the 2013 Financing, the Company also issued a warrant to its placement agent to purchase up to 61,250 shares of common stock at an exercise price of $3.00 per share of common stock (the “Agent’s Warrant”). The Agent’s Warrant became exercisable on September 4, 2013 and will expire on October 9, 2017. The fair value of the Agent’s Warrant issued is $115,150, calculated using the Black-Scholes-Merton valuation model value of $1.88 with an expected and contractual life of 4.6 years, an assumed volatility of 111.9%, and a risk-free interest rate of 0.85%.
	2012 FINANCING
	As described in Note 1 and in connection with the 2012 Financing, on January 20, 2012, the Company entered into a Convertible Note and Warrant Purchase Agreement (the “Purchase Agreement”) with certain strategic accredited investors (the “Investors”), pursuant to which the Company issued and sold to the Investors, in a private placement, subordinated mandatorily convertible promissory notes (collectively, the “Notes”) with an aggregate principal amount of $10 million. The Company also issued warrants (the “2012 Warrants”) to the Investors to purchase an aggregate of 1,739,132 shares of the Company's common stock, par value $0.01 per share. The 2012 Warrants cover a number of shares of common stock equal to 20% of the principal amount of the Notes purchased by each Investor, divided by $1.15.  The 2012 Warrants have an exercise price of $1.40 per share and became exercisable on July 29, 2012 and expire on July 29, 2017. The relative fair value of the 2012 Warrants issued was $2,155,527, calculated using the Black-Scholes-Merton valuation model value of $1.58 with an expected and contractual life of 5.5 years, an assumed volatility of 103%, and a risk-free interest rate of 0.71%. The 2012 Warrants were recorded as additional paid-in-capital and a discount on the Notes of $2,155,527 was fully amortized as non-cash interest expense during the year ended December 31, 2012 as a result of the conversion of the Notes.
	The 2012 Financing was completed on February 2, 2012. The Company received net proceeds of approximately $9.3 million. The Company paid one of the investors, in a related-party transaction, a fee in the amount of 6% of the aggregate amount raised in the 2012 Financing. In connection with the 2012 Financing, the Company incurred a total of $683,955 of debt issuance costs. All debt issuance costs were fully amortized and recorded as interest expense upon conversion of the Notes in the second quarter of 2012.
	The Company received approval of the 2012 Financing from the Company's stockholders at the 2012 annual stockholders meeting held on April 30, 2012. On May 1, 2012, the Notes, including accrued interest of $144,658, automatically and immediately converted into 8,821,431 shares of common stock and the 2012 Warrants became exercisable as of July 29, 2012.  The Notes bore an interest rate of 6% and converted at a conversion price of $1.15 per share.  The conversion price reflected the 10-day average closing sale price of the Company’s common stock ended on January 20, 2012.
	The Notes were not convertible, and the 2012 Warrants were not exercisable, prior to receiving stockholder approval. The Notes contained a contingent beneficial conversion feature as the conversion price of the shares was less than the share price on the date of the Notes issuance. The beneficial conversion feature was valued at $7,057,153 and was recorded as non-cash interest expense and additional paid-in-capital in the second quarter of 2012, upon removal of the contingency and conversion of the Notes on May 1, 2012.

SHAREBASED_COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	7. SHARE-BASED COMPENSATION
	The Company has adopted incentive and nonqualified stock option plans for executive, scientific and administrative personnel of the Company as well as outside directors and consultants. In May 2013, the Company’s shareholders approved an amendment to the 2011 Long-Term Incentive Plan, increasing the number of shares reserved for issuance from 1,730,000 to 4,230,000 shares of common stock to be available for grants and awards. In April 2012, 150,000 options were granted to the Company’s Chief Executive Officer outside of the Company’s 2011 Long-Term Incentive Plan, as an inducement award material to his employment, in accordance NASDAQ Listing Rule 5635(c)(4). As of December 31, 2013, there are 3,586,394 shares issuable under options previously granted and currently outstanding, with exercise prices ranging from $1.59 to $34.10. In 2012, the Company awarded options to two officers, a portion of which is subject to certain performance conditions and market conditions. Options granted under the plans generally vest over periods varying from immediately to one to three years, are not transferable and generally expire ten years from the date of grant. As of December 31, 2013, 1,110,876 shares remained available for grant under the Company’s 2011 Long-Term Incentive Plan.
	The Company’s net loss for the years ended December 31, 2013 and 2012 includes $2,044,382 and $978,243, respectively, of non-cash compensation expense related to the Company’s share-based compensation awards. The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:
		2013			2012
	Research and development	$	763,470		$	273,204
	General and administrative		1,280,912			705,039
	Share-based compensation expense	$	2,044,382		$	978,243
	Net share-based compensation expense, per common share:
	Basic and diluted	$	0.078		$	0.051
	Stock Options
	The Company uses the Black-Scholes-Merton valuation model to estimate the fair value of service based and performance based stock options granted to employees. For market condition based options, the Company uses a binomial model to estimate fair value. These option valuation models require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.
	Expected Volatility—Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company uses the historical volatility based on the daily price observations of its common stock during the period immediately preceding the share-based award grant that is equal in length to the award’s expected term. EntreMed believes that historical volatility represents the best estimate of future long term volatility.
	Risk-Free Interest Rate—This is the average interest rate consistent with the yield available on a U.S. Treasury note (with a term equal to the expected term of the underlying grants) at the date the option was granted.
	Expected Term of Options—This is the period of time that the options granted are expected to remain outstanding. EntreMed uses a simplified method for estimating the expected term of service based awards granted. For performance based and market based awards, the expected term of service is based on the derived service period.
	Expected Dividend Yield—EntreMed has never declared or paid dividends on its common stock and does not anticipate paying any dividends in the foreseeable future. As such, the dividend yield percentage is assumed to be zero.
	Forfeiture Rate—This is the estimated percentage of options granted that are expected to be forfeited or cancelled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on historical forfeiture experience for similar levels of employees to whom options were granted.
	Following are the weighted-average assumptions used in valuing the stock options granted to employees during the years ended December 31, 2013 and 2012:
		Years ended December 31,
		2013			2012
	Expected volatility	105.3	%		101.67	%
	Risk free interest rate	1.03	%		0.94	%
	Expected term of option	5.77 years			5.74 years
	Forfeiture rate	*5.00	%		*5.00	%
	Expected dividend yield	-			-
	*-Throughout 2013 and 2012, forfeitures were estimated at 5%; the actual forfeiture rate was 0% and 6.4% for 2013 and 2012, respectively. The Company adjusted stock compensation expense for 2013 and 2012 based on the actual forfeiture rate.
	The weighted average fair value of stock options granted was $1.42 and $1.59 in 2013 and 2012, respectively.
	Share-based compensation expense recognized in the Consolidated Statements of Operations is based on awards ultimately expected to vest, net of estimated forfeitures. The authoritative guidance requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	A summary of the Company's stock option plans and of changes in options outstanding under the plans during the years ended December 31, 2013 and 2012 is as follows:
		Number of Options		Weighted Average			Weighted Average	Aggregate Intrinsic
				Exercise Price			Remaining	Value
							Contractual Term
							In years
	Outstanding at December 31, 2011	621,889		$	16.23
	Exercised	-1,136		$	1.76
	Granted	1,249,000		$	2.04
	Expired	-197,833		$	21.13
	Forfeited	-35,376		$	4.69
	Outstanding at December 31, 2012	1,636,544		$	5.07
	Exercised	-3,817		$	1.88
	Granted	2,034,500		$	1.78
	Expired	-80,833		$	27.37
	Forfeited	-		$	-
	Outstanding at December 31, 2013	3,586,394		$	2.69		8.64	$	-
	Vested and expected to vest	3,512,769		$	2.71		8.48	$	-
	at December 31, 2013
	Exercisable at December 31, 2013	2,113,901		$	3.26		8.24	$	-
	The aggregate intrinsic value is calculated as the difference between (i) the closing price of the common stock at December 31, 2013 and (ii) the weighted average exercise price of the underlying awards, multiplied by the number of options that had an exercise price less than the closing price on the last trading day of 2013. The total intrinsic value of options exercised during the years ended December 31, 2013 and 2012 totaled approximately $2,500 and $400, respectively.
	Cash received from option exercises under all share-based payment arrangements for the years ended December 31, 2013 and 2012 was $7,190 and $1,999, respectively. Due to the availability of net operating loss carryforwards and research tax credits, tax deductions for option exercises were not recognized in the years ended December 31, 2013 and 2012.
	The following summarizes information about stock options granted to employees and directors outstanding at December 31, 2013:
		Options Outstanding						Options Exercisable
				Weighted
				Average		Weighted				Weighted
		Number		Remaining		Average		Number		Average
	Range of	Outstanding at		Contractual		Exercise		Exercisable at		Exercise
	Exercise Prices	December 31, 2013		Life in Years		Price		December 31, 2013		Price
	$0.00 - $3.00	3,305,701		9		$	1.88	1,844,333		$	1.92
	$3.01 - $10.00	178,040		6.6		$	6.55	166,915		$	6.58
	$10.01 - $20.00	61,070		3		$	17.28	61,070		$	17.28
	$20.01 - $30.00	20,814		0.5		$	23.72	20,814		$	23.72
	$30.01 - $40.00	20,769		1.6		$	34.09	20,769		$	34.09
		3,586,394		8.6		$	2.69	2,113,901		$	3.26
	As of December 31, 2013, there was approximately $1,911,000 of total unrecognized compensation cost related to non-vested stock options. That cost is expected to be recognized over a weighted-average period of 1.5 years.
	Warrants
Warrants granted generally expire after 3-5 years from the date of grant. Stock warrant activity to non-employees is as follows:
			Weighted Average
	Number of Shares		Exercise Price
Outstanding at December 31, 2011	333,387		$	4.13
Granted	1,739,132		$	1.4
Exercised	-		$	-
Expired	-22,725		$	22
Outstanding at December 31, 2012	2,049,794		$	1.62
Granted	2,309,162		$	2.91
Exercised	-37,391		$	1.4
Expired	-		$	-
Outstanding at December 31, 2013	4,321,565		$	2.31
Exercisable at December 31, 2013	4,321,565		$	2.31

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	8. COMMITMENTS AND CONTINGENCIES
	COMMITMENTS
	ENMD-2076. In January 2006, the Company acquired Miikana, a private biotechnology company. Pursuant to the Merger Agreement, the Company acquired all of the outstanding capital stock of Miikana Therapeutics, Inc. In 2008, EntreMed initiated a Phase 1 clinical trial with its Aurora A and angiogenic kinase inhibitor, ENMD-2076, in patients with solid tumors. A dosing of the first patient with ENMD-2076 triggered a purchase price adjustment milestone of $2 million, which the Company opted to pay in stock. As ENMD-2076 successfully completed Phase 1 clinical trials and advanced to Phase 2, the dosing of the first patient in 2010 triggered an additional purchase price adjustment milestone of $3 million, which was paid stock in 2010. Under the terms of the merger agreement, the former Miikana stockholders may earn up to an additional $4 million of potential payments upon the satisfaction of additional clinical and regulatory milestones for ENMD-2076 and up to the $9 million of potential milestone payments that pertain to a preclinical program that the Company has discontinued. As of December 31, 2013, a $4 million potential milestone payment remains, payable in cash or shares of stock at our option, related to the ENMD-2076 program and the dosing of the first patient in a phase 3 pivotal trial.
	MKC-1. Through the acquisition, the Company acquired rights to MKC-1, a Phase 2 clinical candidate licensed from Hoffman-LaRoche, Inc. (“Roche”) by Miikana in April 2005. Under the terms of the agreement, Roche may be entitled to receive future payments upon successful completion of Phase 3 developmental milestones. The Company does not anticipate reaching any of these milestones in 2014. Roche is also eligible to receive royalties on sales and certain one-time payments based on attainment of annual sales milestones. The Company is also obligated to make certain “success fee” payments to ProPharma based on successful completion of developmental milestones under the Roche license agreement. MKC-1 is currently not under active clinical evaluation.
	2ME2 NCD (2-methoxyestradiol, NanoCrystal Dispersion, 2ME2 NCD) for Oncology. In January 2006, the Company entered into a License Agreement with Elan in which the Company has been granted rights to utilize Elan’s proprietary NanoCrystal Technology in connection with the development of the oncology product candidate, 2ME2 NCD. Under the terms of the License Agreement, Elan is eligible to receive payments upon the achievement of certain clinical, manufacturing, and regulatory milestones and to receive royalty payments based on sales of 2ME2 NCD. Additionally, under the agreement and the corresponding Services Agreement, Elan has the right to manufacture EntreMed’s 2ME2 NCD. Milestones related to the initiation of Phase 2 clinical trials for 2ME2 NCD have been paid and there are no additional milestones achieved as of December 31, 2013. The Company has discontinued clinical development of 2ME2 NCD for oncology.
	Endostatin and Angiostatin for Eye Diseases. The Company is a party to a February 2004 agreement with Children’s Medical Center Corporation (“CMCC”) and Alchemgen Therapeutics pertaining to Endostatin and Angiostatin proteins, programs which have been discontinued by the Company, and pursuant to which Alchemgen received rights to market Endostatin and Angiostatin in Asia. In April 2008, the Company was advised that Alchemgen Therapeutics ceased operations, therefore eliminating our ability to receive any royalties from Alchemgen under the agreement. However, the Company is a party to a sublicense agreement with Oxford BioMedica PLC (“Oxford”) to develop and market Endostatin and Angiostatin for ophthalmologic (eye) diseases. Pursuant to this sublicense, the Company is eligible to receive a portion of upfront payments and royalties from Oxford based on a portion of the payments received and net sales of gene products of Endostatin and Angiostatin and certain development milestone payments. There was no royalty payment received in 2013 or 2012. The Company does not control the drug development efforts of Oxford and has no information or control over when or whether any milestones will be reached that would result in additional payments to the Company in 2014 or beyond.
	2ME2 (2-methoxyestradiol, 2ME2) for Oncology. The Company entered into a license agreement with CMCC for the exclusive, world-wide, royalty-bearing license to 2ME2, an inhibitor of angiogenesis. In consideration for retaining the 2ME2 rights, the Company must pay a royalty on any sublicensing fees, as defined in the agreement, to Children's Hospital, Boston. The agreement obligates the Company to pay up to $1,000,000 “upon the attainment of certain milestones.” As of December 31, 2013, the Company has paid $500,000 under this agreement for the milestones that have been achieved to date. The Company has discontinued research and development of 2ME2 for oncology and currently is evaluating 2ME2 for possible other indications.
	ENMD-2076 is the only program currently under active clinical evaluation by the Company. Pursuant to the Company’s commitments for ENMD-2076, it could potentially pay $4 million, in stock or cash at the Company’s election, when the next development milestone is reached. With respect to the Company’s other product candidates, which are not actively pursued or have been discontinued pursuant to the commitments detailed above, in aggregate, the Company could potentially pay up to $41 million if each licensed product candidate is fully developed and approved for commercial use in all of the major territories of the world. In this event, the Company would also be obligated to pay annual sales-based royalties under the license agreements. However, the Company does not expect any of the other product candidates will reach additional developmental milestones in 2014 and accordingly does not anticipate any future milestone payments for these programs.
	As of December 31, 2013, the Company also has purchase obligation commitments, in the normal course of business, for clinical trial contracts totaling $395,000.
	The Company leases its principal executive offices in Rockville, MD under a lease agreement that continues through December 31, 2016. The Company leases office space in China under a lease agreement that continues through June 2017. Effective February 1, 2014, the Company entered into a one year lease in China for lab space. Rent expense is recognized under the straight-line method.
	The future minimum payments under its facilities leases are as follows:
	2014	$	233,040
	2015		163,309
	2016		161,338
	2017		39,214
	Thereafter		-
	Total minimum payments	$	596,901
	Rental expense for the years ended December 31, 2013 and 2012 was $175,000 and $152,000, respectively.
	CONTINGENCIES
	EntreMed is subject in the normal course of business to various legal proceedings in which claims for monetary or other damages may be asserted. Management does not believe such legal proceedings, unless otherwise disclosed herein, are material.

EMPLOYEE_RETIREMENT_PLAN

EMPLOYEE RETIREMENT PLAN	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Compensation and Employee Benefit Plans [Text Block]	'
	9. EMPLOYEE RETIREMENT PLAN
	The Company sponsors the EntreMed, Inc. 401(k) and Trust. The plan covers substantially all employees and enables participants to contribute a portion of salary and wages on a tax-deferred basis. Contributions to the plan by the Company are discretionary. Contributions by the Company totaled approximately $21,614 and $26,500 in 2013 and 2012, respectively.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Segment Reporting, Policy [Policy Text Block]	'
	SEGMENT INFORMATION
	The Company currently operates in one business segment, which is the development of targeted therapeutics primarily for the treatment of cancer. The Company is managed and operated as one business. EntreMed’s senior management team reports to the Board of Directors and is responsible for aligning the Company’s business strategy with its core scientific strengths, while maintaining prudent resource management, fiscal responsibility and accountability. The Company employs a drug development strategy in the United States and China to develop targeted therapeutics for the global market and its current lead drug candidate is ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer.
	The Company does not operate separate lines of business with respect to its product candidates. Accordingly, the Company does not have separately reportable segments as defined by authoritative guidance issued by the Financial Accounting Standards Board (FASB).
Research and Development Expense, Policy [Policy Text Block]	'
	RESEARCH AND DEVELOPMENT
	Research and development expenses consist primarily of compensation and other expenses related to research and development personnel, research collaborations, costs associated with pre-clinical correlative testing and clinical trials of our drug candidate, including the costs of manufacturing drug substance and drug product, regulatory maintenance costs, and facilities expenses. Research and development costs are expensed as incurred, including costs incurred in filing, defending and maintaining patents.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	PROPERTY AND EQUIPMENT
	Furniture and equipment and leasehold improvements are stated at cost and are depreciated over their estimated useful lives of 3 to 10 years. Depreciation and amortization is determined on a straight-line basis. Depreciation and amortization expense was $17,389 and $20,457 in 2013 and 2012, respectively.
	Property and equipment consists of the following:
		DECEMBER 31,
		2013		2012
	Furniture and equipment	$	248,732	$	235,093
	Leasehold improvements		6,382		101,026
			255,114		336,119
	Less: accumulated depreciation and amortization		-176,972		-283,563
		$	78,142	$	52,556
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	IMPAIRMENT OF LONG-LIVED ASSETS
	In accordance with authoritative guidance issued by FASB, the Company periodically evaluates the value reflected in its balance sheet of long-lived assets, such as equipment, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Such events and circumstances include the use of the asset in current research and development projects, any potential alternative uses of the asset in other research and development projects in the short to medium term and restructuring plans entered into by the Company. No impairment charges were recorded in 2013 and 2012.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	CASH AND CASH EQUIVALENTS
	Cash and cash equivalents include cash and highly liquid investments with original maturities of less than 90 days. Substantially all of the Company's cash equivalents are held in short-term money market accounts.
Receivables, Policy [Policy Text Block]	'
	ACCOUNTS RECEIVABLE
	Accounts receivable are stated net of allowances for doubtful accounts.  Allowances for doubtful accounts are determined on a specific item basis.  Management reviews the credit worthiness of individual customers and past payment history to determine the allowance for doubtful accounts.  There is an allowance for doubtful accounts of $12,536 at December 31, 2013 and 2012.
	As of December 31, 2012, one customer represented 100% of the total accounts receivable.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	'
	FOREIGN CURRENCY TRANSLATION
	The U.S. dollar is the functional and reporting currency of the Company. Foreign currency denominated assets and liabilities of the Company and all of its subsidiaries are translated into U.S. dollars. Accordingly, monetary assets and liabilities are translated using the exchange rates in effect at the consolidated balance sheet date and revenues and expenses at the rates of exchange prevailing when the transactions occurred. Remeasurement adjustments are included in income.
Deferred Charges, Policy [Policy Text Block]	'
	DEFERRED RENT
	The Company accounts for rent expense related to operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense in each fiscal year is recorded as an adjustment to deferred rent. Deferred rent as of December 31, 2013 and 2012 was $6,871 and $2,029, respectively, and is included in accrued liabilities in the accompanying consolidated balance sheets.
Debt, Policy [Policy Text Block]	'
	DEBT ISSUANCE COST
	Amortization expense of debt issuance costs is calculated using the interest method over the term of the debt and is recorded in interest expense for 2012 in the accompanying consolidated statements of operations.
Convertible Notes With Detachable Warrants And Beneficial Conversion Feature [Policy Text Block]	'
	CONVERTIBLE NOTES WITH DETACHABLE WARRANTS AND BENEFICIAL CONVERSION FEATURE
	The Company accounts for the issuance of detachable stock purchase warrants in accordance with Accounting Standards Codification (ASC) Topic 470, whereby the proceeds received from convertible notes are allocated between the convertible notes and the detachable warrants based on the relative fair value of the convertible notes without the warrants and the warrants. The portion of the proceeds allocated to the warrants is recognized as additional paid-in capital and a debt discount. The debt discount related to warrants is accreted into interest expense through maturity of the notes.
	In accordance with the provisions of ASC Topic 470, the Company allocated a portion of the proceeds received in connection with the 2012 Financing to the embedded beneficial conversion feature, based on the difference between the effective conversion price of the proceeds allocated to the convertible notes and the fair value of the underlying common stock on the date the convertible notes were issued. Since the convertible notes also had detachable stock purchase warrants, the Company first allocated the proceeds to the stock purchase warrants and the convertible notes and then allocated the resulting convertible notes proceeds between the beneficial conversion feature, which was accounted for as paid-in capital, and the initial carrying amount of the convertible notes. The discount resulting from the beneficial conversion feature is recorded as a debt discount.
Expenses For Clinical Trials [Policy Text Block]	'
	EXPENSES FOR CLINICAL TRIALS
	Expenses for clinical trials are incurred from planning through patient enrollment to reporting of the data. The Company estimates expenses incurred for clinical trials that are in process based on patient enrollment and based on clinical data collection and management. Costs that are associated with patient enrollment are recognized as each patient in the clinical trial completes the enrollment process. Estimated clinical trial costs related to enrollment can vary based on numerous factors, including expected number of patients in trials, the number of patients that do not complete participation in a trial, and the length of participation for each patient. Costs that are based on clinical data collection and management are recognized in the reporting period in which services are provided. In the event of early termination of a clinical trial, the Company accrues an amount based on estimates of the remaining non-cancelable obligations associated with winding down the clinical trial. As of December 31, 2013 and 2012, clinical trial accruals were $244,192 and $222,304, respectively, and are included in accounts payable in the accompanying consolidated balance sheets.
Income Tax, Policy [Policy Text Block]	'
	INCOME TAXES
	Income tax expense is accounted for in accordance with authoritative guidance issued by FASB. Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.
	The Company accounts for uncertain tax positions pursuant to the guidance of FASB ASC Topic 740, Income Taxes. The Company recognizes interest and penalties related to uncertain tax positions, if any, in income tax expense. As of December 31, 2013 and 2012, the Company did not accrue any interest related to uncertain tax positions. To date, there have been no interest or penalties charged to the Company in relation to the underpayment of income taxes.
Revenue Recognition, Policy [Policy Text Block]	'
	REVENUE RECOGNITION
	Revenue is not recognized until it is realized or realizable and earned. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price to the buyer is fixed and determinable and collectibility is reasonably assured. Royalties from licenses are based on third-party sales and recorded as earned in accordance with contract terms, when third-party results are reliably measured and collectibility is reasonably assured.
	All of the Company’s 2012 revenues were from royalties based on the sale of Thalomid®, distributed by Celgene Corporation (“Celgene”). In 2004, certain provisions of a purchase agreement dated June 14, 2001 by and between Bioventure Investments kft (“Bioventure”) and the Company were satisfied, and, as a result, in 2005 the Company became entitled to share in the royalty payments received by Royalty Pharma Finance Trust, successor to Bioventure, on annual Thalomid® sales above a certain threshold. Based on the licensing agreement royalty formula, the Company’s right to share in the annual royalty commences when net royalties received by Royalty Pharma exceeds $15,375,000. The Company did not recognize any royalty revenue in 2013, as it did not meet the threshold to earn royalties on the sale of Thalomid® in 2013. The Company does not expect to earn royalties from the sale of Thalomid® in any subsequent year.
Earnings Per Share, Policy [Policy Text Block]	'
	NET LOSS PER SHARE
	Net loss per share (basic and diluted) was computed by dividing net loss attributable to common shareholders by the weighted average number of shares of common stock outstanding. Outstanding options and warrants totaling 7,907,959 and 3,686,338 for 2013 and 2012, respectively, were anti-dilutive and, therefore, were not included in the computation of weighted average shares used in computing diluted loss per share.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	SHARE-BASED COMPENSATION
	The Company records compensation expense associated with service, performance, market condition based stock options and other equity-based compensation in accordance with provisions of authoritative guidance. The fair value of awards whose fair values are calculated using the Black-Scholes option pricing model is generally being amortized on a straight-line basis over the requisite service period and is recognized based on the proportionate amount of the requisite service period that has been rendered during each reporting period. The fair value of awards with market conditions, which are valued using a binomial model, is being amortized based upon the derived service period. Share based awards granted to employees with a performance condition are measured based on the probable outcome of that performance condition during the requisite service period. Awards with performance conditions will be expensed if it is probable that the performance condition will be achieved. As of December 31, 2013, no expense has been recorded for share awards with performance conditions.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	NEW ACCOUNTING PRONOUNCEMENTS
	EntreMed has implemented all new accounting pronouncements that are in effect and that may impact the Company’s consolidated financial statements, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements.
Fair Value Of Financial Instruments And Concentrations Of Risk [Policy Text Block]	'
	FAIR VALUE OF FINANCIAL INSTRUMENTS AND CONCENTRATIONS OF RISK
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured amounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. The carrying amount of current assets and liabilities approximates their fair values due to their short-term maturities.
Use of Estimates, Policy [Policy Text Block]	'
	USE OF ESTIMATES
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our most critical accounting estimates relate to accounting policies for clinical trial accruals and share-based arrangements. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances. Actual results may differ from those estimates, and such differences may be material to the consolidated financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consists of the following:
		DECEMBER 31,
		2013		2012
	Furniture and equipment	$	248,732	$	235,093
	Leasehold improvements		6,382		101,026
			255,114		336,119
	Less: accumulated depreciation and amortization		-176,972		-283,563
		$	78,142	$	52,556

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
	Significant components of the Company's deferred income tax assets and liabilities as of December 31, 2013 and 2012 are as follows:
		DECEMBER 31,
		2013		2012
	Deferred income tax assets (liabilities):
	Net operating loss carryforwards	$	134,395,000	$	132,994,000
	Research and development credit carryforward		9,037,000		9,019,000
	Equity investment		72,000		72,000
	Other		4,361,000		3,665,000
	Depreciation		4,000		64,000
	Valuation allowance for deferred income tax assets		-147,869,000		-145,814,000
	Net deferred income tax assets	$	-	$	-
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	A reconciliation of the provision for income taxes to the federal statutory rate is as follows:
		2013		2012
	Tax benefit at statutory rate	$	-1,951,000	$	-4,945,000
	State taxes		-217,000		-701,000
	Net R&D credit adjustment		-122,000		-97,000
	Attribute expiration and other		8,000		4,068,000
	Disallowed expenses		2,000		1,000
	Change in valuation allowance		2,055,000		2,015,000
	Other		231,000		67,000
	Change in tax rates		-6,000		-408,000
		$	-	$	-
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:
		2013		2012
	Unrecognized tax benefits balance at January 1	$	3,006,000	$	3,103,000
	Reductions for Tax Positions of Prior Periods		-26,000		-97,000
	Additions for Tax Positions of Current Period		33,000		-
	Unrecognized tax benefits balance at December 31	$	3,013,000	$	3,006,000

SHAREBASED_COMPENSATION_Tables

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The compensation expense related to the Company’s share-based compensation arrangements is recorded as components of general and administrative expense and research and development expense, as follows:
		2013			2012
	Research and development	$	763,470		$	273,204
	General and administrative		1,280,912			705,039
	Share-based compensation expense	$	2,044,382		$	978,243
	Net share-based compensation expense, per common share:
	Basic and diluted	$	0.078		$	0.051
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Following are the weighted-average assumptions used in valuing the stock options granted to employees during the years ended December 31, 2013 and 2012:
		Years ended December 31,
		2013			2012
	Expected volatility	105.3	%		101.67	%
	Risk free interest rate	1.03	%		0.94	%
	Expected term of option	5.77 years			5.74 years
	Forfeiture rate	*5.00	%		*5.00	%
	Expected dividend yield	-			-
	*-Throughout 2013 and 2012, forfeitures were estimated at 5%; the actual forfeiture rate was 0% and 6.4% for 2013 and 2012, respectively. The Company adjusted stock compensation expense for 2013 and 2012 based on the actual forfeiture rate.
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the Company's stock option plans and of changes in options outstanding under the plans during the years ended December 31, 2013 and 2012 is as follows:
		Number of Options		Weighted Average			Weighted Average	Aggregate Intrinsic
				Exercise Price			Remaining	Value
							Contractual Term
							In years
	Outstanding at December 31, 2011	621,889		$	16.23
	Exercised	-1,136		$	1.76
	Granted	1,249,000		$	2.04
	Expired	-197,833		$	21.13
	Forfeited	-35,376		$	4.69
	Outstanding at December 31, 2012	1,636,544		$	5.07
	Exercised	-3,817		$	1.88
	Granted	2,034,500		$	1.78
	Expired	-80,833		$	27.37
	Forfeited	-		$	-
	Outstanding at December 31, 2013	3,586,394		$	2.69		8.64	$	-
	Vested and expected to vest	3,512,769		$	2.71		8.48	$	-
	at December 31, 2013
	Exercisable at December 31, 2013	2,113,901		$	3.26		8.24	$	-
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	The following summarizes information about stock options granted to employees and directors outstanding at December 31, 2013:
		Options Outstanding						Options Exercisable
				Weighted
				Average		Weighted				Weighted
		Number		Remaining		Average		Number		Average
	Range of	Outstanding at		Contractual		Exercise		Exercisable at		Exercise
	Exercise Prices	December 31, 2013		Life in Years		Price		December 31, 2013		Price
	$0.00 - $3.00	3,305,701		9		$	1.88	1,844,333		$	1.92
	$3.01 - $10.00	178,040		6.6		$	6.55	166,915		$	6.58
	$10.01 - $20.00	61,070		3		$	17.28	61,070		$	17.28
	$20.01 - $30.00	20,814		0.5		$	23.72	20,814		$	23.72
	$30.01 - $40.00	20,769		1.6		$	34.09	20,769		$	34.09
		3,586,394		8.6		$	2.69	2,113,901		$	3.26
Warrant Activity To Non Employees [Table Text Block]	'
	Warrants granted generally expire after 3-5 years from the date of grant. Stock warrant activity to non-employees is as follows:
				Weighted Average
		Number of Shares		Exercise Price
	Outstanding at December 31, 2011	333,387		$	4.13
	Granted	1,739,132		$	1.4
	Exercised	-		$	-
	Expired	-22,725		$	22
	Outstanding at December 31, 2012	2,049,794		$	1.62
	Granted	2,309,162		$	2.91
	Exercised	-37,391		$	1.4
	Expired	-		$	-
	Outstanding at December 31, 2013	4,321,565		$	2.31
	Exercisable at December 31, 2013	4,321,565		$	2.31

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	The future minimum payments under its facilities leases are as follows:
	2014	$	233,040
	2015		163,309
	2016		161,338
	2017		39,214
	Thereafter		-
	Total minimum payments	$	596,901

DESCRIPTION_OF_BUSINESS_AND_BA1

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012
Description of Business and Basis of Presentation [Line Items]	'	'	'
Proceeds from Convertible Debt	'	'	$10,000,000
Warrants Issued During The Period	2,247,912	'	'
Issuance of common stock (in shares)	4,495,828	'	'
Equity Method Investment, Ownership Percentage	'	100.00%	'
Retained Earnings (Accumulated Deficit), Total	'	-399,069,608	-393,331,247
Proceeds from Issuance or Sale of Equity, Total	'	$10,789,987	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Furniture and equipment	$248,732	$235,093
Leasehold improvements	6,382	101,026
Property, Plant and Equipment, Gross	255,114	336,119
Less: accumulated depreciation and amortization	-176,972	-283,563
Property, Plant and Equipmen, net	$78,142	$52,556

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Accounting Policies [Line Items]	'	'
Depreciation	$17,389	$20,457
Allowance for doubtful accounts	12,536	12,536
Percentage Of Account Receivable	'	100.00%
Clinical Trial Accruals	244,192	222,304
Royalties Received Exceeds Amount	15,375,000	'
Warrants and Rights Outstanding	7,907,959	3,686,338
Deferred Rent Credit, Current	$6,871	$2,029
Furniture And Equipment [Member]	'	'
Accounting Policies [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'3 years	'
Leasehold Improvements [Member]	'	'
Accounting Policies [Line Items]	'	'
Property, Plant and Equipment, Useful Life	'10 years	'

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	1 Months Ended
	Feb. 28, 2013	Dec. 31, 2012
		Emerging Technology Partners LLC [Member]
Related Party Transaction [Line Items]	'	'
Payment Of Advisory Fee In Percentage	'	6.00%
Payment To Related Party	$86,683	'

LICENSE_AGREEMENTS_Details_Tex

LICENSE AGREEMENTS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2004
License Agreements [Line Items]	'	'	'
Maximum Purchase To Be Made For Potential Purchase Price Adjustment	'	'	$800,000,000
Royalties Revenue	$0	$669,310	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred income tax assets (liabilities):	'	'
Net operating loss carryforwards	$134,395,000	$132,994,000
Research and development credit carryforward	9,037,000	9,019,000
Equity investment	72,000	72,000
Other	4,361,000	3,665,000
Depreciation	4,000	64,000
Valuation allowance for deferred income tax assets	-147,869,000	-145,814,000
Net deferred income tax assets	$0	$0

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]	'	'
Tax benefit at statutory rate	($1,951,000)	($4,945,000)
State taxes	-217,000	-701,000
Net R&D credit adjustment	-122,000	-97,000
Attribute expiration and other	8,000	4,068,000
Disallowed expenses	2,000	1,000
Change in valuation allowance	2,055,000	2,015,000
Other	231,000	67,000
Change in tax rates	-6,000	-408,000
Total	$0	$0

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule Of Unrecognized Tax Benefits Roll Forward [Line Items]	'	'
Unrecognized tax benefits balance at January 1	$3,006,000	$3,103,000
Reductions for Tax Positions of Prior Periods	-26,000	-97,000
Additions for Tax Positions of Current Period	33,000	0
Unrecognized tax benefits balance at December 31	$3,013,000	$3,006,000

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax [Line Items]	'	'	'
Unrecognized Tax Benefits	$3,013,000	$3,006,000	$3,103,000
Operating Loss Carryforwards	343,555,000	339,553,000	'
Operating Loss Carryforwards Expiration Period	'Expire in years 2018 through 2033	'	'
Reductions for Tax Positions of Prior Periods	-26,000	-97,000	'
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	33,000	0	'
United States [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	-5,314,629	'	'
China [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total	-423,732	'	'
Research Tax Credit Carryforward [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Unrecognized Tax Benefits	'	3,006,000	'
Tax Credit Carryforward, Amount	9,037,000	'	'
Operating Loss Carryforwards Expiration Period	'Expire in years 2018 through 2033	'	'
Employee Stock Option [Member]	'	'	'
Income Tax [Line Items]	'	'	'
Operating Loss Carryforwards	$20,000,000	'	'

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS' EQUITY (Details Textual) (USD $)	1 Months Ended	12 Months Ended		0 Months Ended	1 Months Ended	3 Months Ended		12 Months Ended		1 Months Ended
	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Feb. 02, 2012	31-May-12	Mar. 31, 2013	Mar. 31, 2013	Dec. 31, 2002	Apr. 30, 2012	Apr. 30, 2012
				Financing 2012 [Member]	Financing 2012 [Member]	Financing 2013 [Member]	Agent Warrant [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]
										Financing 2012 [Member]
Stockholders Equity [Line Items]	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	'	'	'	'	'	'	'	'	'	1,522,727
Common stock, shares issued	'	27,119,974	22,582,938	'	'	4,495,828	'	'	'	'
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	'	'	'	1,739,132	'	2,247,912	61,250	'	'	'
Class Of Warrant Or Right Par Value Of Securities Called By Warrants Or Rights	'	'	'	$0.01	'	'	'	'	'	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	'	'	1.4	'	2.91	3	'	'	'
Fair Value Assumptions, Expected Term	'	'	'	'5 years 6 months	'	'3 years 6 months	'4 years 7 months 6 days	'	'	'
Fair Value Assumptions, Risk Free Interest Rate	'	'	'	0.71%	'	0.40%	0.85%	'	'	'
Gross Proceeds From Issuance Of Shares And Warrants	'	'	'	'	'	$10,800,000	'	'	'	'
Class Of Warrant Or Right Description Of Securities Called By Warrants	'	'	'	'The 2012 Warrants cover a number of shares of common stock equal to 20% of the principal amount of the Notes purchased by each Investor, divided by $1.15.	'	'	'	'	'	'
Class Of Warrant Or Right Maturity Period Description	'	'	'	'The 2012 Warrants have an exercise price of $1.40 per share and became exercisable on July 29, 2012 and expire on July 29, 2017.	'	'The 2013 Warrants have an exercise price of $2.91 per share and became exercisable on September 4, 2013 and expire on September 4, 2016.	'The Agents Warrant became exercisable on September 4, 2013 and will expire on October 9, 2017.	'	'	'
Fair Value Of Warrant Issued	'	'	'	2,155,527	'	3,574,180	115,150	'	'	'
Fair Value Assumptions Fair Value	'	'	'	$1.58	'	$1.59	$1.88	'	'	'
Debt Instrument, Unamortized Discount	'	'	'	2,155,527	'	'	'	'	'	'
Debt Conversion, Converted Instrument, Amount	'	'	'	'	144,658	'	'	'	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	'	8,821,431	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	'	6.00%	6.00%	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price	'	'	'	'	$1.15	'	'	'	'	'
Debt Instrument, Convertible, Beneficial Conversion Feature	'	'	7,057,153	'	7,057,153	'	'	'	'	'
Fair Value Assumptions, Expected Volatility Rate	'	'	'	103.00%	'	102.30%	111.90%	'	'	'
Debt Issuance Cost	'	'	'	683,955	'	'	'	'	'	'
Proceeds from Debt, Net of Issuance Costs	'	'	'	9,300,000	'	'	'	'	'	'
Net Proceeds From Issuance Of Common Stock	'	'	'	'	'	10,300,000	'	'	'	'
Market Value Of Common Stock	'	'	'	'	'	'	'	$9.46	'	'
Accumulated Unpaid Dividend	'	'	'	'	'	'	'	'	9,380,000	'
Accumulated Unpaid Dividend Per Share	'	'	'	'	'	'	'	'	$2.80	'
Preferred Stock, Dividend Rate, Percentage	'	6.00%	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues	4,495,828	'	'	'	'	'	'	3,350,000	'	'
Preferred Stock, Conversion Basis	'	'	'	'	'	'	'	'The Series A Preferred Stock was convertible, at the option of Celgene, at any time, into common stock at an initial per common share conversion price of $11.00 (1 share of preferred converts into .45 shares of common).	'	'
Convertible Debt	'	'	'	$10,000,000	'	'	'	'	'	'

SHAREBASED_COMPENSATION_Detail

SHARE-BASED COMPENSATION (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	$2,044,382	$978,243
Net share-based compensation expense, per common share:	'	'
Basic and diluted (in dollars per share)	$0.08	$0.05
Research and Development Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	763,470	273,204
General and Administrative Expense [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Allocated Share-based Compensation Expense	$1,280,912	$705,039

SHAREBASED_COMPENSATION_Detail1

SHARE-BASED COMPENSATION (Details 1)	12 Months Ended
	Dec. 31, 2013		Dec. 31, 2012
Share Based Compensation [Line Items]	'		'
Expected volatility	105.30%		101.67%
Risk free interest rate	1.03%		0.94%
Expected term of option	'5 years 9 months 7 days		'5 years 8 months 26 days
Forfeiture rate	5.00%	[1]	5.00%	[1]
Expected dividend yield	0.00%		0.00%
[1]	Throughout 2013 and 2012, forfeitures were estimated at 5%; the actual forfeiture rate was 0% and 6.4% for 2013 and 2012, respectively. The Company adjusted stock compensation expense for 2013 and 2012 based on the actual forfeiture rate.

SHAREBASED_COMPENSATION_Detail2

SHARE-BASED COMPENSATION (Details 2) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]	'	'
Share Based Compensation [Line Items]	'	'
Outstanding - Number of Options, Beginning Balance	1,636,544	621,889
Exercised - Number of Options	-3,817	-1,136
Granted - Number of Options	2,034,500	1,249,000
Expired - Number of Options	-80,833	-197,833
Forfeited - Number of Options	0	-35,376
Outstanding - Number of Options, Ending Balance	3,586,394	1,636,544
Vested and expected to vest at December 31, 2013	3,512,769	'
Exercisable - Number of Options at December 31, 2013	2,113,901	'
Outstanding - Weighted Average Exercise Price, Beginning balance	$5.07	$16.23
Exercised - Weighted Average Exercise Price	$1.88	$1.76
Granted - Weighted Average Exercise Price	$1.78	$2.04
Expired - Weighted Average Exercise Price	$27.37	$21.13
Forfeited - Weighted Average Exercise Price	$0	$4.69
Outstanding - Weighted Average Exercise Price	$2.69	$5.07
Vested and expected to vest - Weighted Average Exercise Price, Ending Balance	$2.71	'
Exercisable - Weighted Average Exercise Price at December 31, 2013	$3.26	'
Outstanding - Weighted Average Remaining Contractual Term In years	'8 years 7 months 20 days	'
Vested and expected to vest - Weighted Average Remaining Contractual Term In years	'8 years 5 months 23 days	'
Exercisable - Weighted Average Remaining Contractual Term In years	'8 years 2 months 26 days	'
Outstanding - Aggregate Intrinsic Value	$0	'
Vested and expected to vest - Aggregate Intrinsic Value	0	'
Exercisable - Aggregate Intrinsic Value	$0	'

SHAREBASED_COMPENSATION_Detail3

SHARE-BASED COMPENSATION (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013
Share Based Compensation [Line Items]	'
Number Of Options Outstanding at December 31, 2013	3,586,394
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'8 years 7 months 6 days
Number Of Options Outstanding Weighted Average Exercise Price	$2.69
Number Of Options Exercisable at December 31, 2013	2,113,901
Number Of Options Exercisable Weighted Average Exercise Price	$3.26
Range One [Member]	'
Share Based Compensation [Line Items]	'
Range of Exercise Prices Lower Range Limit	$0
Range of Exercise Prices Upper Range Limit	$3
Number Of Options Outstanding at December 31, 2013	3,305,701
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'9 years
Number Of Options Outstanding Weighted Average Exercise Price	$1.88
Number Of Options Exercisable at December 31, 2013	1,844,333
Number Of Options Exercisable Weighted Average Exercise Price	$1.92
Range Two [Member]	'
Share Based Compensation [Line Items]	'
Range of Exercise Prices Lower Range Limit	$3.01
Range of Exercise Prices Upper Range Limit	$10
Number Of Options Outstanding at December 31, 2013	178,040
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'6 years 7 months 6 days
Number Of Options Outstanding Weighted Average Exercise Price	$6.55
Number Of Options Exercisable at December 31, 2013	166,915
Number Of Options Exercisable Weighted Average Exercise Price	$6.58
Range Three [Member]	'
Share Based Compensation [Line Items]	'
Range of Exercise Prices Lower Range Limit	$10.01
Range of Exercise Prices Upper Range Limit	$20
Number Of Options Outstanding at December 31, 2013	61,070
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'3 years
Number Of Options Outstanding Weighted Average Exercise Price	$17.28
Number Of Options Exercisable at December 31, 2013	61,070
Number Of Options Exercisable Weighted Average Exercise Price	$17.28
Range Four [Member]	'
Share Based Compensation [Line Items]	'
Range of Exercise Prices Lower Range Limit	$20.01
Range of Exercise Prices Upper Range Limit	$30
Number Of Options Outstanding at December 31, 2013	20,814
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'6 months
Number Of Options Outstanding Weighted Average Exercise Price	$23.72
Number Of Options Exercisable at December 31, 2013	20,814
Number Of Options Exercisable Weighted Average Exercise Price	$23.72
Range Five [Member]	'
Share Based Compensation [Line Items]	'
Range of Exercise Prices Lower Range Limit	$30.01
Range of Exercise Prices Upper Range Limit	$40
Number Of Options Outstanding at December 31, 2013	20,769
Number Of Options Outstanding Weighted Average Remaining Contractual Life in Years	'1 year 7 months 6 days
Number Of Options Outstanding Weighted Average Exercise Price	$34.09
Number Of Options Exercisable at December 31, 2013	20,769
Number Of Options Exercisable Weighted Average Exercise Price	$34.09

SHAREBASED_COMPENSATION_Detail4

SHARE-BASED COMPENSATION (Details 4) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Share Based Compensation [Line Items]	'	'
Outstanding at Number of Shares, Beginning Balance	2,049,794	333,387
Granted Number of Shares	2,309,162	1,739,132
Exercised Number of Shares	-37,391	0
Expired Number of Shares	0	-22,725
Outstanding at Number of Shares, Ending Balance	4,321,565	2,049,794
Exercisable Number of Shares	4,321,565	'
Outstanding Weighted Average Exercise Price, Beginning Balance	$1.62	$4.13
Granted Weighted Average Exercise Price	$2.91	$1.40
Exercised Weighted Average Exercise Price	$1.40	$0
Expired Weighted Average Exercise Price	$0	$22
Outstanding Weighted Average Exercise Price, Ending Balance	$2.31	$1.62
Exercisable Weighted Average Exercise Price	$2.31	'

SHAREBASED_COMPENSATION_Detail5

SHARE-BASED COMPENSATION (Details Textual) (USD $)

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Apr. 30, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

31-May-13

Dec. 31, 2013

31-May-13

Deferred Compensation, Share-based Payments [Member]

Deferred Compensation, Share-based Payments [Member]

Chief Executive Officer [Member]

Maximum [Member]

Minimum [Member]

Long Term Incentive Plan2011 [Member]

Long Term Incentive Plan2011 [Member]

Long Term Incentive Plan2011 [Member]

Long Term Incentive Plan2011 [Member]

Long Term Incentive Plan2011 [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Minimum [Member]

Share Based Compensation [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

$34.10

'

$1.59

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

$1.42

$1.59

'

'

'

'

'

'

'

'

'

'

Proceeds from Stock Options Exercised

$7,190

$1,999

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Estimated Forfeiture Rate

5.00%

5.00%

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross

'

'

'

'

150,000

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

'

'

'

'

'

'

'

1,110,876

'

4,230,000

'

1,730,000

Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Issuable

'

'

'

'

'

'

'

3,586,394

'

'

'

'

Share Based Compensation Actual Forfeiture Rate

0.00%

6.40%

'

'

'

'

'

'

'

'

'

'

Unrecognized Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period

1,911,000

'

'

'

'

'

'

'

'

'

'

'

Unrecognised Share Based Compensation Cost Expected To Be Recognized Over Weighted Average Period

'1 year 6 months

'

'

'

'

'

'

'

'

'

'

'

Net Income (Loss) Attributable to Parent, Total

-5,738,361

-14,545,224

2,044,382

978,243

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$2,500

$400

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Granted Expire Terms

'

'

'

'

'

'5 years

'3 years

'

'

'

'

'

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2013
Future Minimum Rental Payments For Operating Leases [Line Items]	'
2014	$233,040
2015	163,309
2016	161,338
2017	39,214
Thereafter	0
Total minimum payments	$596,901

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies Disclosure [Line Items]	'	'
Business Combination Consideration Milestone Achievement	$4,000,000	'
Business Combination Consideration Milestone Achievement Consideration Due	4,000,000	'
Up Front Licensing Fees	1,000,000	'
Milestone Achievement Obligation Amount Paid	500,000	'
Additional Amount Upon Milestone Obligation Achievement	41,000,000	'
Purchase Obligation Commitment For Clinical Trial Contracts	395,000	'
Operating Leases, Rent Expense	175,000	152,000
Phase One [Member]	'	'
Commitments And Contingencies Disclosure [Line Items]	'	'
Business Combination Consideration Milestone Achievement	2,000,000	'
Phase Two [Member]	'	'
Commitments And Contingencies Disclosure [Line Items]	'	'
Business Combination Consideration Milestone Achievement	3,000,000	'
Phase Three [Member]	'	'
Commitments And Contingencies Disclosure [Line Items]	'	'
Business Combination Consideration Milestone Achievement	4,000,000	'
Phase Four [Member]	'	'
Commitments And Contingencies Disclosure [Line Items]	'	'
Business Combination Consideration Milestone Achievement	$9,000,000	'

EMPLOYEE_RETIREMENT_PLAN_Detai

EMPLOYEE RETIREMENT PLAN (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Retirement Plan [Line Items]	'	'
Defined Benefit Plan, Contributions by Employer	$21,614	$26,500